article thumbnail

2024 forecast: M&A saw an uptick in 2023. Analysts expect the trend to continue

Fierce Pharma

And it is with cautious optimism that industry watchers see the trend continuing in 2024. . | Even with the Federal Trade Commission keeping a watchful eye on the biopharma industry and the economic landscape giving some players pause, mergers and acquisitions are back on the rise.

Biopharma 350
article thumbnail

Pharma firepower, M&A surge last year bode well for dealmaking prospects in 2024: EY

Fierce Pharma

In it’s annual Firepower report, EY says the biopharma industry enters 2024 with the capability and motivation to increase M&A activity. The late surge of activity in 2023 also bodes well for a 2024 uptick, the group said. Morgan Healthcare Conference. |

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

AstraZeneca CEO's 2024 pay proposal under fire from influential proxy advisers

Fierce Pharma

The two most influential proxy advisory firms are rallying investors to vote against the 2024 pay proposal for Soriot at the company’s annual general meeting this month. Like clockwork, AstraZeneca CEO Pascal Soriot’s pay is under fire again. Like clockwork, AstraZeneca CEO Pascal Soriot’s pay is under fire again.

306
306
article thumbnail

WuXi Biologics stays the course with positive 2024 outlook as national security crackdown threatens business in US

Fierce Pharma

WuXi Biologics stays the course with positive 2024 outlook as national security crackdown threatens business in US fkansteiner Wed, 03/27/2024 - 13:12

290
290
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

📆 November 21, 2024 at 11:00 AM PST, 2:00 PM EST, 7:00 PM GMT

article thumbnail

Pfizer tacks on $1B to 2024 revenue outlook amid cost-cutting drive

Fierce Pharma

For the first time since its sales peaked during the pandemic, Pfizer registered year-over-year revenue growth during the second quarter of 2024. For more than a year after Pfizer’s COVID product sales peaked at the end of 2022, the company’s quarterly revenues showed year-over-year declines. |

Sales 299
article thumbnail

Novo Nordisk, Eli Lilly's obesity drugs will lead in new drug sales in 2024: Evaluate

Fierce Pharma

Expect more of the same in 2024, according to a report from Evaluate, which places Novo and Lilly in the top two spots for global new sales.

Sales 321